Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1993 1
2000 1
2003 1
2004 1
2006 1
2007 2
2009 2
2010 1
2011 3
2012 1
2014 3
2015 1
2016 1
2017 3
2018 1
2019 4
2020 4
2021 2
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Managing injection-induced seismic risks.
Lee KK, Ellsworth WL, Giardini D, Townend J, Ge S, Shimamoto T, Yeo IW, Kang TS, Rhie J, Sheen DH, Chang C, Woo JU, Langenbruch C. Lee KK, et al. Among authors: sheen dh. Science. 2019 May 24;364(6442):730-732. doi: 10.1126/science.aax1878. Science. 2019. PMID: 31123121 No abstract available.
Comparison of the efficacy and safety of LBAL, a candidate adalimumab biosimilar, and adalimumab reference product in patients with active rheumatoid arthritis inadequately responding to methotrexate: a 52-week phase III randomised study.
Matsuno H, Kang YM, Okada M, Lee SI, Park SH, Sheen DH, Sato M, Hagino A, Lee J, Shin S, Song YW. Matsuno H, et al. Among authors: sheen dh. Clin Exp Rheumatol. 2022 May;40(5):1025-1033. doi: 10.55563/clinexprheumatol/cyudn8. Epub 2021 Jul 7. Clin Exp Rheumatol. 2022. PMID: 34251303 Clinical Trial.
Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study.
Park MC, Matsuno H, Kim J, Park SH, Lee SH, Park YB, Lee YJ, Lee SI, Park W, Sheen DH, Choe JY, Choi CB, Hong SJ, Suh CH, Lee SS, Cha HS, Yoo B, Hur JW, Kim GT, Yoo WH, Baek HJ, Shin K, Shim SC, Yang HI, Kim HA, Park KS, Choi IA, Lee J, Tomomitsu M, Shin S, Lee J, Song YW. Park MC, et al. Among authors: sheen dh. Arthritis Res Ther. 2019 May 21;21(1):122. doi: 10.1186/s13075-019-1910-2. Arthritis Res Ther. 2019. PMID: 31113455 Free PMC article. Clinical Trial.
28 results